Positive effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study
Authors:
- X Antón AlvarezXAX Antón Alvarez
- Carolina SampedroCSCarolina Sampedro
- Paula PérezPPPaula Pérez
- Marta LaredoMLMarta Laredo
- Verónica CouceiroVCVerónica Couceiro
- Angeles HernándezAHAngeles Hernández
- Jesús FigueroaJFJesús Figueroa
- Miguel VarelaMVMiguel Varela
- Dulce AriasDADulce Arias
- Lola CorzoLCLola Corzo
- Raquel ZasRZRaquel Zas
- Valter LombardiVLValter Lombardi
- 1 September 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 18 (5) , 271-278
Abstract
The potential effects of Cerebrolysin (EBEWE Pharma, Unterach, Austria), a peptide preparation with neurotrophic activity, on brain bioelectrical activity, cognitive performance and clinical outcome in postacute traumatic brain injury (TBI) patients, were investigated in an exploratory study. A decrease in slow electroencephalogram (EEG) activity and an increase in fast frequencies were observed after the administration of Cerebrolysin. This EEG-activating effect was not influenced by TBI time course or severity, nor by the chronic treatment with nootropic compounds. Cognitive performance, evaluated with the Syndrome Kurztest test, improved in TBI patients after Cerebrolysin treatment, independent of disease severity, time course or disability. A significant improvement in the patients' clinical outcome, only evident during the first year after brain trauma, was also found following Cerebrolysin infusions. No relevant changes in biological parameters nor drug-related adverse events were observed. These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials.Keywords
This publication has 34 references indexed in Scilit:
- Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agentJournal of Neural Transmission, 2002
- Performance Characteristics of Postacute Traumatic Brain Injury Patients on the WAIS-III and WMS-IIIThe Clinical Neuropsychologist, 2001
- Neuropsychological functioning during the year following severe traumatic brain injuryBrain Injury, 2001
- An EEG Severity Index of Traumatic Brain InjuryThe Journal of Neuropsychiatry and Clinical Neurosciences, 2001
- Traumatic Brain Injury Elevates the Alzheimer's Amyloid Peptide Aβ42 in Human CSF: A Possible Role for Nerve Cell InjuryAnnals of the New York Academy of Sciences, 2000
- IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-α, TGF-β1 and blood–brain barrier functionJournal of Neuroimmunology, 1999
- Therapeutic Effects of CDP‐Choline in Alzheimer's Disease‐Cognition, Brain Mapping, Cerebrovascular Hemodynamics, and Immune FactorsaAnnals of the New York Academy of Sciences, 1996
- Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with Senile Dementia of the Alzheimer Type (SDAT)Pharmacopsychiatry, 1994
- ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical ScaleThe Lancet, 1975
- ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESSThe Lancet, 1974